Cargando…

Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update

Detalles Bibliográficos
Autores principales:	DeRenzo, Christopher, Gottschalk, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904842/ https://www.ncbi.nlm.nih.gov/pubmed/27313973 http://dx.doi.org/10.4172/2155-9899.1000417

Ejemplares similares

Genetically Modified T Cells to Target Glioblastoma
por: Krebs, Simone, et al.
Publicado: (2013)

Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors
por: DeRenzo, Christopher, et al.
Publicado: (2019)

A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells
por: Talbot, Lindsay Jones, et al.
Publicado: (2021)

B7-h3-specific engager T cells for the immunotherapy of pediatric solid tumors
por: DeRenzo, Christopher, et al.
Publicado: (2015)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

IMMU-01. Combining CD28 and 4-1BB costimulationin trans enhances the anti-glioma efficacy and persistence of B7-H3 CAR T cells in immune-competent brain tumor models
por: Haydar, Dalia, et al.
Publicado: (2022)

Informed consent in medical research
por: DeRenzo, E G
Publicado: (2001)

CD47 expression is critical for CAR T-cell survival in vivo
por: Beckett, Alex N, et al.
Publicado: (2023)

Special issues raised by evolving areas of clinical research
por: DeRenzo, Evan G., et al.
Publicado: (2020)

Pediatric Osteosarcoma: An Updated Review
por: Taran, Shachi Jain, et al.
Publicado: (2017)

Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells
por: Nguyen, Phuong, et al.
Publicado: (2020)

The Genetics of Osteosarcoma
por: Martin, Jeff W., et al.
Publicado: (2012)

An update on the roles of circular RNAs in osteosarcoma
por: Li, Zheng, et al.
Publicado: (2020)

CAR T-cell design dependent remodeling of the brain tumor immune microenvironment identify macrophages as key players that inhibit or promote anti-tumor activity
por: Haydar, Dalia, et al.
Publicado: (2023)

A prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life
por: Bascou, Nicholas, et al.
Publicado: (2018)

HA-DOPE-Modified Honokiol-Loaded Liposomes Targeted Therapy for Osteosarcoma
por: Zhang, Xiangxiang, et al.
Publicado: (2022)

Practical interfacing in the laboratory: Using a PC for instrumentation, data Analysis and control
por: Derenzo, Stephen E
Publicado: (2003)

CAR T-cell Design-dependent Remodeling of the Brain Tumor Immune Microenvironment Modulates Tumor-associated Macrophages and Anti-glioma Activity
por: Haydar, Dalia, et al.
Publicado: (2023)

Combinatorial Treatment of DNA and Chromatin-Modifying Drugs Cause Cell Death in Human and Canine Osteosarcoma Cell Lines
por: Thayanithy, Venugopal, et al.
Publicado: (2012)

Update on Disease-Modifying/Preventive Therapies in Alzheimer’s Disease
por: Apter, Jeffrey T., et al.
Publicado: (2015)

Cellular and Genetic Background of Osteosarcoma
por: Urlić, Inga, et al.
Publicado: (2023)

A developmental and genetic classification for malformations of cortical development: update 2012
por: Barkovich, A. James, et al.
Publicado: (2012)

Genetically modified mesenchymal stromal cells in cancer therapy
por: Sage, Elizabeth K., et al.
Publicado: (2016)

Adjuvant Biophysical Therapies in Osteosarcoma
por: Carina, Valeria, et al.
Publicado: (2019)

Origin and Therapies of Osteosarcoma
por: Moukengue, Brice, et al.
Publicado: (2022)

Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies
por: Rathore, Richa, et al.
Publicado: (2021)

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
por: Tian, Hailong, et al.
Publicado: (2023)

Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics
por: Simpson, Siobhan, et al.
Publicado: (2017)

A Review of T-Cell Related Therapy for Osteosarcoma
por: Yoshida, Kazushige, et al.
Publicado: (2020)

Phytic acid-modified manganese dioxide nanoparticles oligomer for magnetic resonance imaging and targeting therapy of osteosarcoma
por: Ju, Qian, et al.
Publicado: (2023)

Genetically modified T cells in cancer therapy: opportunities and challenges
por: Sharpe, Michaela, et al.
Publicado: (2015)

Clinical application of genetically modified T cells in cancer therapy
por: Kershaw, Michael H, et al.
Publicado: (2014)

Design studies for a PET detector module using a PIN photodiode to measure depth of interaction
por: Moses, W W, et al.
Publicado: (1993)

Scintillators for positron emission tomography
por: Moses, W W, et al.
Publicado: (1995)

ROS-Generating Hyaluronic Acid-Modified Zirconium Dioxide-Acetylacetonate Nanoparticles as a Theranostic Platform for the Treatment of Osteosarcoma
por: Chianese, Giovanna, et al.
Publicado: (2022)

Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies
por: Abarrategi, Ander, et al.
Publicado: (2016)

An Update on Molecular Pathways Regulating Vasculogenic Mimicry in Human Osteosarcoma and Their Role in Canine Oncology
por: Massimini, Marcella, et al.
Publicado: (2021)

Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies
por: Koike, Haruki, et al.
Publicado: (2020)

Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma
por: Yu, Diana, et al.
Publicado: (2015)

Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment
por: Li, Jing, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9hocfdvd686ivqe4nhkbr8bc8r